Home
GILD
GILD News

Latest Gilead Sciences Inc. (GILD) News on May 19, 2025

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Business Wire

4 days ago

Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

ACCESS Newswire

4 days ago

Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Zacks

4 days ago

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Insider Monkey

6 days ago

Why Gilead Sciences (GILD) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

StockStory

7 days ago

Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know

Trump expected to sign order to slash US drug prices

Yahoo Finance Video

7 days ago

Trump expected to sign order to slash US drug prices

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

Zacks

7 days ago

The Zacks Analyst Blog Highlights Disney, Gilead Sciences, Eaton and Maui Land & Pineapple

US-China trade truce, April CPI, drug prices: 3 Things

Yahoo Finance Video

7 days ago

US-China trade truce, April CPI, drug prices: 3 Things

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

StockStory

7 days ago

GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

Insider Monkey

8 days ago

Is Gilead Sciences (GILD) Among the Best Stocks to Buy According to Jim Simons’ Renaissance Technologies?

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Motley Fool

9 days ago

2 High-Yield Dividend Stocks to Buy in May and Hold Forever

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

Zacks

10 days ago

Top Analyst Reports for Walt Disney, Gilead Sciences & Eaton

3 Value Stocks with Mounting Challenges

StockStory

11 days ago

3 Value Stocks with Mounting Challenges

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

Clinical Trials Arena

11 days ago

Gilead reports final outcomes from trial of bulevirtide for chronic HDV

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Benzinga

12 days ago

How To Put $100 In Your Retirement Fund Each Month With Gilead Sciences Stock

Gilead to Invest $11 Billion to Bolster Domestic Operations

The Wall Street Journal

12 days ago

Gilead to Invest $11 Billion to Bolster Domestic Operations

Investing.com

12 days ago

Gilead Sciences to invest $11 billion in U.S. R&D and manufacturing

Gilead boosts planned US investments by $11 billion amid tariff threat

Reuters

12 days ago

Gilead boosts planned US investments by $11 billion amid tariff threat

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Simply Wall St.

12 days ago

Gilead Sciences (NasdaqGS:GILD) Presents Promising Data On Livdelzi And Bulevirtide At EASL 2025

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Business Wire

13 days ago

Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Business Wire

13 days ago

Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

ACCESS Newswire

13 days ago

Fighting the World's Most Devastating Diseases Is the Focus of This Installment of "The Centrifuge Sessions"

MT Newswires

14 days ago

Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Zacks

14 days ago

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Argus Research

14 days ago

Market Digest: BAX, CAH, CCEP, EPD, EQIX, GILD, MCO, MGM, MSI, RJF, RTX, GM, META, APTV, XYZ

Argus Research

14 days ago

Analyst Report: Gilead Sciences, Inc.

1 Profitable Stock on Our Watchlist and 2 to Turn Down

StockStory

15 days ago

1 Profitable Stock on Our Watchlist and 2 to Turn Down

MT Newswires

17 days ago

Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

Simply Wall St.

18 days ago

Gilead Sciences' (NASDAQ:GILD) Performance Is Even Better Than Its Earnings Suggest

Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

Zacks

19 days ago

Should You Buy, Sell or Hold GILD Stock Post Q1 Earnings Miss?

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Zacks

19 days ago

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire

20 days ago

Gilead Sciences to Present at Upcoming Investor Conferences

MT Newswires

20 days ago

Sector Update: Health Care Stocks Gain Late Afternoon

MT Newswires

20 days ago

Sector Update: Health Care

MT Newswires

20 days ago

Update: Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

MT Newswires

20 days ago

Gilead Sciences to Pay $202 Million in Settlement of Illegal Kickbacks Lawsuit

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

ACCESS Newswire

20 days ago

Gilead Sciences: AIDSVu Online Mapping Tool Helps Visualize HIV’s Impact in the United States

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

Business Wire

20 days ago

Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis

MT Newswires

21 days ago

HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating

Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks

The Wall Street Journal

22 days ago

Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks

Gilead Sciences First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

23 days ago

Gilead Sciences First Quarter 2025 Earnings: Misses Expectations

Why Gilead Sciences Stock Slipped Today

Motley Fool

24 days ago

Why Gilead Sciences Stock Slipped Today

Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.

Investor's Business Daily

24 days ago

Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.

MT Newswires

24 days ago

Gilead Delivers Lackluster Q1 Revenue on Trodelvy Miss, Oppenheimer Says

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Zacks

24 days ago

GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue

Investopedia

24 days ago

Gilead Sciences Stock Falls as Slumping COVID-19, Cancer Drug Sales Hit Revenue

MT Newswires

24 days ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating

MT Newswires

24 days ago

Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating

Thomson Reuters StreetEvents

24 days ago

Q1 2025 Gilead Sciences Inc Earnings Call

MT Newswires

24 days ago

Morgan Stanley Raises Price Target on Gilead Sciences to $135 From $130, Keeps Overweight Rating

3 High Growth Tech Stocks Leading The US Market

Simply Wall St.

24 days ago

3 High Growth Tech Stocks Leading The US Market

MT Newswires

24 days ago

RBC Lifts Price Target on Gilead Sciences to $92 From $89, Keeps Sector Perform Rating

Argus Research

24 days ago

Technical Assessment: Neutral in the Intermediate-Term

Morningstar Research

24 days ago

Analyst Report: Gilead Sciences, Inc.

Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.

Barrons.com

24 days ago

Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks

25 days ago

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

MT Newswires

a month ago

TD Cowen Adjusts Gilead Sciences Price Target to $110 From $100, Maintains Buy Rating

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Zacks

a month ago

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

StockStory

a month ago

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

Gilead reports topline data from Phase III trial of Trodelvy combo therapy

Clinical Trials Arena

a month ago

Gilead reports topline data from Phase III trial of Trodelvy combo therapy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Insider Monkey

a month ago

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Investing.com

a month ago

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Zacks

a month ago

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

Simply Wall St.

a month ago

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

MT Newswires

a month ago

Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Zacks

a month ago

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Business Wire

a month ago

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

Zacks

a month ago

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings

Zacks

a month ago

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Zacks

a month ago

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

MT Newswires

a month ago

BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115

MT Newswires

a month ago

Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

a month ago

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

MT Newswires

a month ago

Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

Zacks

a month ago

Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know

MT Newswires

a month ago

Gilead Sciences Insider Sold Shares Worth $266,000, According to a Recent SEC Filing

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

Zacks

a month ago

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?

Insider Monkey

a month ago

Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now?

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks

a month ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

MT Newswires

a month ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating

Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program

ACCESS Newswire

a month ago

Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program

3 Reasons GILD is Risky and 1 Stock to Buy Instead

StockStory

a month ago

3 Reasons GILD is Risky and 1 Stock to Buy Instead

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

The Wall Street Journal

a month ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

Business Wire

a month ago

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

PatientView Ranks Gilead "Best" at ESG

ACCESS Newswire

a month ago

PatientView Ranks Gilead "Best" at ESG

MT Newswires

a month ago

Ideaya Biosciences Begins Phase 1/2 Expansion in Urothelial Cancer Treatment Trial in Combination With Gilead's Trodelvy

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

Zacks

a month ago

Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Zacks

a month ago

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1

Insider Monkey

a month ago

Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1

2 Top Dividend Stocks That Could Set You Up for Life

Motley Fool

a month ago

2 Top Dividend Stocks That Could Set You Up for Life

Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections

ACCESS Newswire

a month ago

Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

Zacks

a month ago

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

Argus Research

a month ago

Technical Assessment: Neutral in the Intermediate-Term

4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues

Zacks

a month ago

4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Zacks

2 months ago

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

MT Newswires

2 months ago

RBC Trims Price Target on Gilead Sciences to $89 From $90, Keeps Sector Perform Rating

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

Zacks

2 months ago

Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Zacks

2 months ago

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Zacks

2 months ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

2 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Share on Social Networks: